identified 295 spinal injury patients, with a mean age at index of 44 years, an average follow-up time of 6 years, and of which 79% were males. For 67% of the population we observed at least one UTI, which resulted in a care contact. Interestingly, a quarter of the population used prophylactic antibiotics (J01XX05), corresponding to an average of 235 DDDs per year, amongst users. A majority of UTIs were handled in primary care, while over 90% of costs were contributed by UTIrelated hospitalisations. The mean cost per UTI was 43,500 SEK, while estimates varied considerably, with costs ranging from an average of 1,800 SEK for UTIs handled in primary care to 177,200 SEK for inpatient care. CONCLUSIONS: In a population of spinal injury patients, costs for catheter-associated urinary tract infections are to a large extent driven by outlier, expensive hospitalisation. There would be a large potential for cost savings if these hospitalisations could be avoided. 
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PMD55 RESOURCE UTILISATION RELATED TO URINARY TRACT INFECTIONS IN SWEDISH SELF-CATHETERISATION PATIENTS

OBJECTIVES:
To collect real-life data on costs and resource use, in order to understand the economic burden of urinary tract infection (UTI) amongst a population who has received self-catheterisation training. METHODS: We used the CEBRxA database, which combines data from a public claims database for the South-West region of Sweden, comprising around 1.5 million individuals, with national Swedish registers on drug utilisation and mortality. We identified a population of patients who had received self-catheterisation training anytime between 2006 and 2009(procedure code GB005). UTIs were identified through the following ICD-10 codes: N11.0, N30*, N39.0*, N39.X*, N12.-P, and N30.-P. A cost per UTI was calculated through considering UTI-related care contacts that occurred within 14 days from each other. RESULTS: We identified 989 patients, with a high mean age at index of 65 years, 79% males, and an average follow-up time of 1.5 years. The disease burden of this population was mainly related to the genitourinary system, like retention of urine, benign prostate hyperplasia, cystitis, and neurogenic bladder, although essential hypertonia emerged as the third most common comorbidity. We observed an average frequency of one UTI every two years, while around one-fifth of patients had a yearly UTI-frequency of one or above. A majority of UTIs were handled in primary care, while around 80% of costs were contributed by UTI-related hospitalisations. However, among female patients, inpatient care only contributed to 60% of total costs. The mean cost per UTI was 10,500 SEK, while estimates varied, with average costs ranging from 2,100 SEK in primary care, to 32,000 SEK for inpatient care. CONCLUSIONS: Patients having received self-catheterisation training were on average of higher age and male. UTI-related hospitalisation was a clear driver of costs, although this effect was less pronounced for women. OBJECTIVES: Approximately 880,000 tonsillectomy/adenoidectomy procedures are performed in the US annually. Hemostatic matrix (FLOSEAL) is used for adjunctive hemostasis in a variety of surgeries, but the health economic rationale supporting its application in tonsillectomy and adenoidectomy has yet to be established. A systematic literature review was conducted in order to examine the evidence for hemostatic matrix and to consider its value in reducing the burden of these procedures. METHODS: Applying keywords and inclusion criteria, the PubMed, EMBASE, and Centre for Reviews and Dissemination databases were queried for studies published in English up to March 1, 2011. Reference lists and the American Academy of Otolaryngology-Head and Neck Surgery database were also manually searched. Data on costs, resource utilization, and health outcomes were extracted and summarized. RESULTS: Four prospective, randomized controlled trials provided data on 187 patients treated with hemostatic matrix. In the two studies utilizing crossover design, no patients in the hemostatic matrix groups required electrocautery, whereas 3 of 35 (9%) and 4 of 34 (12%) patients, respectively, required adjunctive hemostatic matrix intraoperatively after failing electrocautery. In all three studies measuring operating room time, use of hemostatic matrix resulted in significantly shorter mean durations (range, 0.93 to 24.6 minutes) compared to electrocautery (range, 9.53 to 32.6 minutes) (all studies, PϽ0.05). Although postoperative bleeding rates did not differ, hemostatic matrix-treated patients in three of four studies reported significant reductions in postoperative pain scores and narcotic consumption compared to electrocautery-treated patients (PϽ0.05). CONCLUSIONS: Published evidence suggests that hemostatic matrix is effective in achieving intraoperative hemostasis during tonsillectomy/adenoidectomy. Given the high volume of procedures, using hemostatic matrix during tonsillectomy and adenoidectomy may be potentially cost saving due to resulting reductions in operating time and postoperative narcotic consumption. Further research may identify patients who are more likely to benefit from hemostatic matrix in this indication. 
PMD56 A SYSTEMATIC LITERATURE REVIEW ON THE CLINICAL AND ECONOMIC OUTCOMES ATTRIBUTABLE TO THE USE OF HEMOSTATIC MATRIX DURING TONSILLECTOMY AND ADENOIDECTOMY
PMD57 DATA VISUALIZATION FOR BUSINESS INTELLIGENCE: ASSESSING AN ONLINE TOOL USED FOR BENCHMARKING HOSPITAL PROCEDURE COSTS TO REIMBURSMENT IN CARDIAC CATHETERIZATION AND ELECTOPHYSIOLOGY PROCEDURES
Medical Device/Diagnostics -Patient-Reported Outcomes & Preference-Based Studies
PMD58 PROVISION AND FINANCING OF MEDICAL AIDS IN THE MANAGEMENT OF RARE DISEASES: THE CASE OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Henschke C Berlin University of Technology, Berlin, Berlin, Germany
OBJECTIVES:
Patients suffering from ALS have a need for a multitude of medical aids. Existing (bureaucratic) hurdles might create plenty of problems for people with rare diseases. Uncertainty about provision of medical aids and substantial waiting times limit patient's ability to participate in the activities of daily living. This study aims 1) to analyze problems in financing and provision of medical aids; 2) to explore differences in reimbursement decisions of private and social health insurance (SHI); and 3) to explore patient satisfaction according to the type of health insurance. METHODS: First, published and grey literature was used to analyse payment flows and supply chain activities of the various actors involved in the provision and payment of medical aids. Second, a survey of ALS patients (nϭ20) based on semi-standardized questionnaires was conducted . Gathered information included patients' demographic characteristics, information on coverage decisions and problems in the provision of medical aids. Based on patient satisfaction, analysis of variance tests were performed to investigate differences in satisfaction between SHI and privately insured persons. RESULTS: A majority of patients experienced problems in reimbursement decisions, particularly in the case of expensive or individually customized technologies. These reimbursement problems were more common among SHI insured persons. Both SHI insured and privately insured persons complain about long duration processes of individual requests for meeting the cost. Nonetheless, most patients stated that they were satisfied with the actual provision of medical aids, including product and service quality. CONCLUSIONS: Our results suggest that difficulties with medical aids' reimbursement decision processes are a common problem among SHI and private insured ALS patients. Although the patient's insurance type has an impact on these time-consuming process. Consequently, there is a need for an interdisciplinary approach in the provision of medical aids. Case managers might be a solution to overcome these problems. 
PMD59 COMPLICATED PARKINSON'S DISEASE: DISCRETE CHOICE ANALYSIS TO ASSESS PATIENTS' PREFERENCES. A PILOT STUDY
OBJECTIVES:
In advanced or complicated Parkinson's disease (CPD), among other treatment alternatives, patients can receive deep brain stimulation (DBS) or continuous duodenal levodopa-carbidopa infusion (CDLCI). This pilot study was designed to understand the preferences of patients who face these treatment choices. METHODS: Treatment attributes were identified based on a literature review, focus groups with patients, caregivers, and interviews with clinicians. A discrete choice experiment survey was developed, reviewed by clinicians and piloted with patients. Patients (potentially considering DBS or CDLCI) in Spain (nϭ30) and the UK (nϭ10) completed the survey . Treatment attributes included surgery type, impact on daily life, medication need, speech difficulties, movement control, dyskinesia, and off-periods. Data were analyzed using a multi-level hierarchical logistic model. RESULTS: Surgery type (DBS electric lead insertion in the brain vs CDLCI intraduodenal tube placement) was the most powerful predictor in the model, with a pref-A254 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
